Stonebridge Capital Advisors LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Stonebridge Capital Advisors LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 35.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,586 shares of the biopharmaceutical company’s stock after buying an additional 6,921 shares during the period. Stonebridge Capital Advisors LLC’s holdings in Pfizer were worth $738,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in PFE. Creekmur Asset Management LLC purchased a new position in Pfizer in the fourth quarter valued at $32,000. Trivant Custom Portfolio Group LLC raised its position in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares in the last quarter. Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer in the 4th quarter valued at about $36,000. DiNuzzo Private Wealth Inc. acquired a new position in shares of Pfizer during the fourth quarter worth about $37,000. Finally, ESL Trust Services LLC purchased a new stake in shares of Pfizer during the first quarter worth approximately $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE PFE traded up $1.00 on Friday, reaching $30.77. The stock had a trading volume of 35,657,080 shares, compared to its average volume of 30,301,530. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The stock has a market cap of $174.36 billion, a P/E ratio of -512.75, a price-to-earnings-growth ratio of 1.18 and a beta of 0.69. The business’s 50-day moving average price is $28.54 and its 200 day moving average price is $27.77. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.19.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.23 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.46%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analyst Ratings Changes

A number of brokerages recently issued reports on PFE. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, July 10th. Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Barclays raised their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 10th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average price target of $34.50.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.